ROCKET PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Stock Option Valuation
The weighted average assumptions that the Company used in a Black-Scholes pricing model to determine the fair value of stock options granted to employees, non-employees and directors were as follows:
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Risk-free interest rate | 2.99% | 4.31% |
| Expected term (in years) | 4.24 | 5.42 |
| Expected volatility | 71.87% | 71.68% |
| Expected dividend yield | 0.00% | 0.00% |
| Exercise price | $4.25 | $10.51 |
| Fair value of common stock | $4.25 | $10.51 |
The following table summarizes stock option activity for thesix months ended June 30, 2026:
| Weighted · Weighted | ||||
|---|---|---|---|---|
| Average · Average · Aggregate | ||||
| Number of | Exercise | Contractual | Intrinsic | |
| Shares | Price | Term (Years) | Value | |
| Outstanding as of December 31, 2025 | 12,163,019 | $19.98 | 4.53 | 706 |
| Granted | 3,433,942 | 4.25 | 7.96 | |
| Exercised | (95,537) | 1.59 | ||
| Cancelled or forfeited | (2,036,132) | 23.45 | ||
| Outstanding as of June 30, 2026 | 13,465,292 | $15.58 | 4.99 | 1,106 |
| Options vested and exercisable as of June 30, 2026 | 8,635,055 | $21.66 | 3.04 | $136 |
| Options unvested as of June 30, 2026 | 4,830,237 | $4.71 | 8.48 | $970 |
The weighted average grant-date fair value per share of stock options granted outside the stock option exchange program during the six months ended June 30, 2026, and 2025 was$3.14 and$5.86, respectively.
The total grant date fair value of options vested during the six months ended June 30, 2026 and 2025 was$5.1 million and$18.8 million, respectively.
Total intrinsic value of options exercised during the six months ended June 30, 2026 and 2025 was$0.1 million and$6.9 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.